title: [Effect of tumor antigen specific CTL induced by dendritic cells on a model of human hepatocellular carcinoma in nude mice (LCI-D20)].
abstract: OBJECTIVE
  To investigate the cure effect of tumor antigen specific CTL on a model of human hepatocellular carcinoma in nude mice LCI-D20.
  
  
  METHODS
  Dendritic cells (DCs) were induced from peripheral blood mononuclear cells of healthy people in vitro by using recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4) and were pulsed with tumor antigen from hepatocellular carcinoma cell line MHCC97H. Then tumor antigen specific cytotoxic T lymphocytes (CTLs) were induced. By intraperitoneal injection of tumour antigen specific CTLs into the LCI-D20, the preventive and therapeutic effects of these CTLs to HCC in the LCI-D20 model were assessed. Cytokine-induced killer (CIK) cells and phosphate buffer solution were used as controls at the same time.
  
  
  RESULTS
  The weights of tumors in the tumor antigen specific CTL group, in the CIK cell group and in the blank group were (1.11+/-0.63), (1.12+/-0.36) and (2.68+/-0.53) grams respectively (t = 5.18, t = 6.06, P < 0.01). The amount of blood alpha fetal protein in the tumor antigen specific CTL and CIK groups were (52.1+/-9.7) microg/L and (48.6+/-5.2) microg/L, and was (82.2+/-7.2) microg/L in the blank group (t = 17.26, t = 22.07, P < 0.01 respectively). The metastasis rates in livers were 16.7%, 16.7% and 58.3% in the tumor antigen specific CTL, CIK cell and blank control groups respectively (chi2= 4.44, P < 0.01). The survival time of the mice in the tumor antigen specific CTL group was (79.0+/-5.02) days, (73.3+/-7.0) days in the CIK group, and (52.3+/-5.2) days in the blank group (t = 14.56, t = 17.54, P < 0.01).
  
  
  CONCLUSIONS
  Tumor antigen specific CTLs may prevent metastasis in the LCI-D20 model and prolong the survival time.
authors.affiliation: Institute for Viral Hepatitis, Chongqing University of Medical Sciences, Chongqing 400010, China.
authors.forename: Guo-lin
authors.initials: GL
authors.lastname: Chen
authors.forename: Huai-dong
authors.initials: HD
authors.lastname: Hu
authors.forename: Ying-ji
authors.initials: YJ
authors.lastname: Ma
authors.forename: Yong-guo
authors.initials: YG
authors.lastname: Li
authors.forename: Qiong
authors.initials: Q
authors.lastname: Xue
authors.forename: Min
authors.initials: M
authors.lastname: Chen
authors.forename: Hong
authors.initials: H
authors.lastname: Ren
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000473:pathology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D011994:Recombinant Proteins; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor